Hepatocellular adenomas (HCAs) are rare benign monoclonal hepatic tumors that commonly occur in females (3-4 per 100,000 women) due to the use of oral contraceptives, its primary risk factor. Recently, HCAs have been classified into 4 distinct subtypes according to genotypic and phenotypic characteristics and clinical features: inflammatory HCA (40-50%), which are hypervascular with marked peliosis and a tendency to bleed; hepatocyte nuclear factor 1α (HNF1A)-mutated HCA (H-HCA, 30-40%) that are diffusely steatotic and rarely undergo malignant transformation; β-catenin activated HCA (10-15%), which frequently undergo malignant transformation and may seem hepatocellular carcinoma on imaging; and unclassified HCA (10-25%). In this study, we report the case of a 23-year-old female oral contraceptive user with H-HCA. Usually, H-HCA is considered to be nonsevere in most cases and often requires outpatient follow-up. However, in this case, the injury had substantially increased in volume and evolved with a major bleeding frame, which was an unusual finding for this subtype of adenoma. The therapeutic used for this patient was a laparoscopic left hepatic segCase
Gustavo Rêgo Coelho mentectomy. Thus, the choice of treatment to be performed in a patient with H-HCA can depend on the tumor size (>5 cm), the outcome of previous bleeding, and the risk of bleeding recurrence.
Background
Hepatocellular adenomas (HCAs) are rare monoclonal benign liver tumors that most commonly occur in women (3-4 per 100,000 women) [1, 2] . HCAs are the third most prevalent benign tumors of the liver and have the capacity to undergo malignant transformation [2, 3, 4] .
Contraceptive use is an important risk factor for developing HCA, and its risk is determined by the time of use and the amount of estrogen present in the oral contraceptive drug. HCA rarely occurs in children and men (male:female ratio = 1:9). Other risk factors for HCAs include the use of anabolic steroids, glycogen storage disease (types Ia, III, and VI), hemochromatosis, androgen therapy, and the use of barbiturates and clomiphene [5] .
Recently, HCA has been classified into 4 distinct subtypes according to genotypic and phenotypic characteristics and clinical features: inflammatory HCA (IHCA, 40-50%), hepatocyte nuclear factor 1α (HNF1A)-mutated HCA (H-HCA, 30-40%), β-catenin activated HCA (b-HCA, 10-15%), and unclassified HCA (UHCA, 10-25%) [1, 6, 7] . IHCA is characterized by the presence of serum and lesional indicators (such as higher serum levels of amyloid A and Creactive protein) of an active inflammatory response; it has also been linked to activating mutations in several genes, including IL6ST, FRK, STAT3, JAK1, and GNAS, and is hypervascular with marked peliosis and a tendency to bleed [6, 8, 9] . IHCA is associated with obesity, alcohol use, and hepatic steatosis. Approximately 10% of the inflammatory subtype can show additional β-catenin activation and may progress to hepatocellular carcinoma (HCC). H-HCA exhibits inactivating mutations in the HNF1A (TCF1) gene causing loss of hepatocyte nuclear factor 1α (HNF-1α) expression and a downregulation of the liver fatty acid-binding protein (LFABP). This subtype is diffusely steatotic, rarely leads to malignant progression, and is associated with familial diabetes or adenomatosis [10] . The subtype b-HCA is related to male hormone administration and glycogen storage disease, typified by activating mutations of β-catenin that resist phosphorylation-mediated downregulation by the GSKB/APC/ AXIN complex. The result is an accumulation of nuclear β-catenin which, combined with deletion of APC, stimulates the progression to HCC [7] . The b-HCA subtype also demonstrates a higher risk of malignant transformation in patients with an HCA larger than 4-5 cm [6, 10] . UHCA is not yet defined by any particular genetic mutation, but is characterized by various histologic criteria that are unusual in the other subtypes; the underlying pathogenesis of this subtype remains unclear [11] .
Patients can present with right upper quadrant pain or a palpable mass. However, up to 50% of patients are asymptomatic. HCAs can be complicated by life-threatening bleeding or undergo malignant transformation necessitating surgical management [12] .
The HCA subtypes show variable complication rates. Hemorrhage can occur in 15-20% of HCAs [13] . Bleeding can be intratumoral, intrahepatic, or extrahepatic. Risk factors for bleeding of HCA include a diameter of 35 mm or more, visualization of central and peripheral intralesional arteries, location in the left lateral liver, and exophytic growth [14] .
Furthermore, 9% of HCA may transform into HCC with risk factors including male sex, androgen use, large tumors (>5 cm), and β-catenin-mutated HCA [15] .
The subclassification system for HCA helps clinicians to stratify patients according to imaging criteria, expression of associated immunohistochemical markers, or molecular findings. These data may influence the treatment selected [16] , since certain subtypes of HCA pose a greater risk of progression to HCC than others. On the other hand, HCAs can arise with atypical characteristics, presenting aspects of more than 1 subtype. Thus, it can require a different therapeutic approach. Herein, we report a case of H-HCA with atypical features, and surgical intervention was necessary.
Case Presentation
A 23-year-old woman with a past medical history of oral contraceptive use for 10 years and metformin hydrochloride use, including no previous surgery or cases of cancer in the family. The patients presented to our medical department with a 2-week history of discrete unspecific abdominal pain. Previous ultrasonography had exhibited a large nodule in the left liver lobe. Then, magnetic resonance imaging was performed, and we found a large heterogeneous expansive nodular lesion in the left liver lobe, partially exophytic, located at the periphery of segments II/III, measuring around 10.3 × 6.8 × 10.7 cm. The nodular lesion was visualized in the contrast medium without "wash-out," noting a significant signal drop in the out-phase sequence, indicating a massive fat component of the lesion (Fig. 1) . These findings are strongly indicative of HNF1A adenoma. However, an intralesional blood component was identified, which was characterized by a high spontaneous signal in the T1 fat-sat sequence, with bleeding being extremely uncommon in the subtype described but more commonly associated with IHCA. Her liver function tests, aspartate aminotransferase and alanine transaminase, exhibited no alterations. Other laboratory testing showed a white cell count of 8.1 × 10 3 /μL (normal range 4.4-11.3 × 10 3 /μL), hemoglobin of 13 g/dL (normal range 12.3-15.3 g/dL), platelet count of 355 × 10 3 /μL (normal range 145-445 × 10 3 /μL), international normalized ratio (INR) of 1.01 (normal value 1) and C-reactive protein of 0.75 mg/dL (normal range <0.8 mg/dL). Tumor marker test revealed α-fetoprotein of 3 ng/mL (negative for malignant tumor).
Despite the bleeding, the important lesional fatty component detected on magnetic resonance imaging was extremely suggestive of H-HCA, a subtype that is generally treated conservatively. However, considering the tumor volume (>5 cm), the presence of intralesional blood component, and the risk of bleeding recurrence, left hepatic segmentectomy was performed.
The nodule sections showed neoplasia characterized by proliferation of hepatocytes in relatively delicate trabeculae, with slightly enlarged nuclei, without significant atypia, with frequent macrovascular steatosis (around 40%), as well as areas of hemorrhage and necrosis (Fig. 2) . Moderate inflammatory cell infiltrate and HCA measuring 11 cm on the largest axis were also found. These morphological changes characterized adenoma associated with inactivation of HNF1-α, according to the diagnosis prior to surgery.
Discussion
We presented the case of a young woman with a history of oral contraceptive use who initially presented with discrete symptoms and an ultrasonography result suggestive of a 
